Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).

Lymphoma and Plasma Cell Disorders
Session Type and Session Title: 
Oral Abstract Session, Myeloma
Abstract Number: 


J Clin Oncol 33, 2015 (suppl; abstr 8510)
Todd M. Zimmerman, Kent A. Griffith, Jagoda Jasielec, Cara Ann Rosenbaum, Kathryn McDonnell, Jessica Waite-Marin, Jesus G. Berdeja, Noopur S. Raje, Donna Ellen Reece, Ravi Vij, Mattina Alonge, Shaun Rosebeck, Sandeep Gurbuxani, Malek Faham, Katherine A Kong, Joan Levy, Andrzej J. Jakubowiak; University of Chicago, Chicago, IL; University of Michigan, Ann Arbor, MI; Northshore University Health System, Evanston, IL; Sarah Cannon Research Institute, Nashville, TN; Massachusetts General Hospital, Boston, MA; Princess Margaret Hospital, Toronto, ON, Canada; Washington University in St Louis School of Medicine, Saint Louis, MO; Sequenta, Inc., South San Francisco, CA; Multiple Myeloma Research Consortium, Norwalk, CT; University of Chicago Medical Center, Chicago, IL

Abstract Disclosures


Background: In a phase I/II study of combination treatment with CFZ, LEN, and DEX (KRd) without ASCT, KRd provided a high rate of sCR (55%) in NDMM patients (pts) and 3-year progression-free survival and OS rates of 79% and 96% (Jakubowiak et al. Blood 2012;120:1801-9; Jasielec et al. Blood 2013;122:3220). To further improve response and outcomes, we designed a phase II study to assess activity of extended treatment with KRd and ASCT. Methods: Pts received 28-day (d) cycles of CFZ 20/36 mg/m2IV (d1, 2, 8, 9, 15, 16), LEN 25mg PO (d1–21), and DEX 40/20 mg PO wkly (cycles1–4 induction/5–8 consolidation) with ASCT after cycle 4. For cycles 8–18, KRd was given with a modified CFZ schedule (d1, 2, 15, 16) and then LEN alone after cycle 18. Response was assessed by IMWG plus nCR. The primary endpoint is the rate of stringent complete response (sCR) at the end of cycle 8, with statistical hypothesis that the improvement of sCR from 30% (KRd without ASCT) to >50% will represent added benefit of ASCT. Results: As of December 31, 2014 the study accrual goal of 53 pts has been met; median age 62 yr (range 40-76), ISS stage II/III 53%, high-risk cytogenetics 27%, as per IMWG. To date, 49 pts completed induction, 41 transplant, 23 consolidation, and 7 have completed 18 cycles of KRd. A median 9.79x106/kg CD34+ cells were collected (range 3.89-16.79). Response improved with each phase of treatment (Table). At the end of 8 cycles, 15/17 evaluable pts (88%) were MRD-negative. After a median follow-up of 9.7 months (range 1.6-23), all pts were alive and 52 of 53 progression free. KRd was well tolerated during induction with no new or unexpected events. After ASCT, KRd-related AEs were mostly Grade (G) 1/; the, most common G3/4 AEs were lymphopenia (50%), leukopenia (14%), and neutropenia (21%). Conclusions: KRd with ASCT for NDMM resulted in higher sCR rates than KRd without ASCT and high rate of MRD-negative disease, suggestive of benefit of adding ASCT to KRd treatment. The results to date compare favorably to any prior treatment of NDMM. Clinical trial information: NCT01816971

≥ PR %98100100100
≥ VGPR %7897100100
≥ nCR %144491100
sCR %10257086